Paraptosis: a non-classical paradigm of cell death for cancer therapy

IF 6.9 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Chun-cao Xu, Yi-fan Lin, Mu-yang Huang, Xiao-lei Zhang, Pei Wang, Ming-qing Huang, Jin-jian Lu
{"title":"Paraptosis: a non-classical paradigm of cell death for cancer therapy","authors":"Chun-cao Xu, Yi-fan Lin, Mu-yang Huang, Xiao-lei Zhang, Pei Wang, Ming-qing Huang, Jin-jian Lu","doi":"10.1038/s41401-023-01159-7","DOIUrl":null,"url":null,"abstract":"Due to the sustained proliferative potential of cancer cells, inducing cell death is a potential strategy for cancer therapy. Paraptosis is a mode of cell death characterized by endoplasmic reticulum (ER) and/or mitochondrial swelling and cytoplasmic vacuolization, which is less investigated. Considerable evidence shows that paraptosis can be triggered by various chemical compounds, particularly in cancer cells, thus highlighting the potential application of this non-classical mode of cell death in cancer therapy. Despite these findings, there remain significant gaps in our understanding of the role of paraptosis in cancer. In this review, we summarize the current knowledge on chemical compound-induced paraptosis. The ER and mitochondria are the two major responding organelles in chemical compound-induced paraptosis, which can be triggered by the reduction of protein degradation, disruption of sulfhydryl homeostasis, overload of mitochondrial Ca2+, and increased generation of reactive oxygen species. We also discuss the stumbling blocks to the development of this field and the direction for further research. The rational use of paraptosis might help us develop a new paradigm for cancer therapy.","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":"45 2","pages":"223-237"},"PeriodicalIF":6.9000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"1089","ListUrlMain":"https://www.nature.com/articles/s41401-023-01159-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Due to the sustained proliferative potential of cancer cells, inducing cell death is a potential strategy for cancer therapy. Paraptosis is a mode of cell death characterized by endoplasmic reticulum (ER) and/or mitochondrial swelling and cytoplasmic vacuolization, which is less investigated. Considerable evidence shows that paraptosis can be triggered by various chemical compounds, particularly in cancer cells, thus highlighting the potential application of this non-classical mode of cell death in cancer therapy. Despite these findings, there remain significant gaps in our understanding of the role of paraptosis in cancer. In this review, we summarize the current knowledge on chemical compound-induced paraptosis. The ER and mitochondria are the two major responding organelles in chemical compound-induced paraptosis, which can be triggered by the reduction of protein degradation, disruption of sulfhydryl homeostasis, overload of mitochondrial Ca2+, and increased generation of reactive oxygen species. We also discuss the stumbling blocks to the development of this field and the direction for further research. The rational use of paraptosis might help us develop a new paradigm for cancer therapy.

Abstract Image

Abstract Image

副突变:用于癌症治疗的非经典细胞死亡范例
由于癌细胞具有持续增殖的潜力,诱导细胞死亡是一种潜在的癌症治疗策略。凋亡是一种以内质网(ER)和/或线粒体肿胀和胞质空泡化为特征的细胞死亡模式,但对这种模式的研究较少。大量证据表明,旁凋亡可由各种化学物质触发,尤其是在癌细胞中,从而凸显了这种非典型细胞死亡模式在癌症治疗中的潜在应用。尽管有这些发现,但我们对副aptosis在癌症中的作用的认识仍有很大差距。在这篇综述中,我们总结了目前关于化合物诱导的副aptosis的知识。ER和线粒体是化合药物诱导的副aptosis的两个主要反应细胞器,蛋白质降解的减少、巯基平衡的破坏、线粒体Ca2+的超载以及活性氧生成的增加都可能引发副aptosis。我们还讨论了这一领域发展的绊脚石和进一步研究的方向。合理利用副aptosis可能有助于我们开发出一种新的癌症治疗模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmacologica Sinica
Acta Pharmacologica Sinica 医学-化学综合
CiteScore
15.10
自引率
2.40%
发文量
4365
审稿时长
2 months
期刊介绍: APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信